Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173546 | 0.72 | PARP15 (0.40) | PARP10 | |
| SCHEMBL1201760 | 0.69 | PARP10 (0.43) | PARP10 | |
| SCHEMBL197768 | 0.66 | — | — | |
| SCHEMBL31276985 | 0.65 | CHRNB2 (0.67) | CHRNB2CHRNA4 | |
| SCHEMBL16845110 | 0.65 | CHRNB2 (0.67) | CHRNB2CHRNA4 | |
| SCHEMBL533308 | 0.65 | — | — | |
| SCHEMBL19837299 | 0.64 | CYP4F2 (0.36) | CHRNB2CHRNA4HRH1MAP4K4ACACB | |
| SCHEMBL20243469 | 0.64 | LMNA (0.34) | — | |
| SCHEMBL231982 | 0.64 | PARP10 (0.48) | HRH1ACACBPARP10 | |
| SCHEMBL25334821 | 0.63 | SLC6A4 (0.37) | HRH1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-7531668-B2 | 2-arylcarboxamide-nitrogenous heterocycle compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MSD K.K. (JP) | 2007-12-27 | — | — | US | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1798221-A1 | 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | MC1R, MCHR2, MCHR1 | CHRNB2 573/4885CHRNA4 712/4885HRH1 163/4885 |
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MCHR2, MCHR1, NPY2R | CHRNB2 648/4885CHRNA4 1115/4885HRH1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.